Establishment of Patient-derived Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumor Models For Predicting Therapeutic Response

  • Yebra M
  • Bhargava S
  • Kumar A
  • et al.
N/ACitations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Purpose: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract with mutant succinate dehydrogenase ( SDH ) subunits (A-D) comprising less than 7.5% (i.e. 150-200/year) of new cases annually in the United States. Contrary to GISTs harboring KIT or PDGFRA mutations, SDH -mutant GISTs affect adolescents/young adults, often metastasize, and are frequently resistant to tyrosine kinase inhibitors (TKIs). Lack of human models for any SDH- mutant tumors, including GIST, has limited molecular characterization and drug discovery. Experimental design: We describe methods for establishing novel patient-derived SDH -mutant (m SDH ) GIST models and interrogated the efficacy of temozolomide on these tumor models in vitro and in clinical trials of m SDH GIST patients. Results: Molecular and metabolic characterization of our patient-derived m SDH GIST models revealed that these models recapitulate the transcriptional and metabolic hallmarks of parent tumors and SDH-deficiency. We further demonstrate that temozolomide elicits DNA damage and apoptosis in our m SDH GIST models. Translating our in vitro discovery to the clinic, a cohort of SDH -mutant GIST patients treated with temozolomide (n=5) demonstrated a 40% objective response rate and 100% disease control rate suggesting that temozolomide represents a promising therapy for this subset of GIST. Conclusion: We report the first methods to establish patient-derived m SDH tumor models, which can be readily employed for understanding patient-specific tumor biology and treatment strategies. We also demonstrate that temozolomide is effective in m SDH GIST patients who are refractory to existing chemotherapeutic drugs (namely TKIs) in clinic for GISTs, bringing a promising treatment option for these patients to clinic.

Cite

CITATION STYLE

APA

Yebra, M., Bhargava, S., Kumar, A., Burgoyne, A. M., Tang, C.-M., Yoon, H., … Sicklick, J. K. (2021). Establishment of Patient-derived Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumor Models For Predicting Therapeutic Response. Clinical Cancer Research, clincanres.2092.2021. https://doi.org/10.1158/1078-0432.ccr-21-2092

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free